Wells Fargo
HRTX icon

Wells Fargo’s Heron Therapeutics HRTX Stock Holding History

Wells Fargo’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.2K Sell
66,543
-113,077
-63% -$131K ﹤0.01% 5435
2025
Q4 		$234K Buy
179,620
+56,488
+46% +$69.7K ﹤0.01% 4976
2025
Q3 		$155K Sell
123,132
-135,116
-52% -$214K ﹤0.01% 5073
2025
Q2 		$535K Buy
258,248
+181,082
+235% +$370K ﹤0.01% 4090
2025
Q1 		$170K Buy
77,166
+2,403
+3% +$4.66K ﹤0.01% 4813
2024
Q4 		$114K Buy
74,763
+13,568
+22% +$22K ﹤0.01% 5124
2024
Q3 		$122K Buy
61,195
+593
+1% +$1.42K ﹤0.01% 4901
2024
Q2 		$212K Buy
60,602
+19,238
+47% +$59.1K ﹤0.01% 4491
2024
Q1 		$115K Buy
41,364
+4,012
+11% +$10.1K ﹤0.01% 4812
2023
Q4 		$63.5K Buy
37,352
+6,843
+22% +$7.54K ﹤0.01% 5174
2023
Q3 		$31.4K Sell
30,509
-21,775
-42% -$31K ﹤0.01% 5409
2023
Q2 		$60.6K Buy
52,284
+21,430
+69% +$38.2K ﹤0.01% 5338
2023
Q1 		$46.6K Buy
30,854
+20,877
+209% +$52.3K ﹤0.01% 5191
2022
Q4 		$24.9K Sell
9,977
-3,772
-27% -$12.2K ﹤0.01% 5170
2022
Q3 		$58K Sell
13,749
-32,089
-70% -$126K ﹤0.01% 4881
2022
Q2 		$128K Sell
45,838
-55,249
-55% -$222K ﹤0.01% 4504
2022
Q1 		$579K Sell
101,087
-3,025
-3% -$22.1K ﹤0.01% 4310
2021
Q4 		$951K Sell
104,112
-64,977
-38% -$663K ﹤0.01% 4156
2021
Q3 		$1.81M Buy
169,089
+2,546
+2% +$31K ﹤0.01% 3752
2021
Q2 		$2.58M Buy
166,543
+55,634
+50% +$885K ﹤0.01% 3453
2021
Q1 		$1.8M Sell
110,909
-98,892
-47% -$1.76M ﹤0.01% 3797
2020
Q4 		$4.44M Sell
209,801
-11,524
-5% -$200K ﹤0.01% 2858
2020
Q3 		$3.28M Sell
221,325
-45,683
-17% -$713K ﹤0.01% 2897
2020
Q2 		$3.93M Buy
267,008
+196,234
+277% +$3.22M ﹤0.01% 2700
2020
Q1 		$831K Buy
70,774
+18,911
+36% +$355K ﹤0.01% 3660
2019
Q4 		$1.22M Sell
51,863
-12,451
-19% -$275K ﹤0.01% 3725
2019
Q3 		$1.19M Sell
64,314
-19,299
-23% -$355K ﹤0.01% 3705
2019
Q2 		$1.55M Sell
83,613
-296,793
-78% -$5.93M ﹤0.01% 3545
2019
Q1 		$9.3M Sell
380,406
-67,524
-15% -$1.77M ﹤0.01% 2002
2018
Q4 		$11.6M Sell
447,930
-6,660
-1% -$183K ﹤0.01% 1760
2018
Q3 		$14.4M Buy
454,590
+188,743
+71% +$7.03M ﹤0.01% 1779
2018
Q2 		$10.3M Buy
265,847
+205,302
+339% +$6.54M ﹤0.01% 2042
2018
Q1 		$1.67M Buy
60,545
+28,095
+87% +$637K ﹤0.01% 3509
2017
Q4 		$587K Sell
32,450
-97,924
-75% -$1.6M ﹤0.01% 4274
2017
Q3 		$2.11M Buy
130,374
+87,212
+202% +$1.37M ﹤0.01% 3275
2017
Q2 		$597K Buy
43,162
+3,583
+9% +$51.9K ﹤0.01% 4099
2017
Q1 		$595K Buy
39,579
+17,442
+79% +$241K ﹤0.01% 4124
2016
Q4 		$290K Buy
22,137
+10,970
+98% +$172K ﹤0.01% 4556
2016
Q3 		$192K Buy
11,167
+1,858
+20% +$34.5K ﹤0.01% 4508
2016
Q2 		$168K Sell
9,309
-2,100
-18% -$41K ﹤0.01% 4501
2016
Q1 		$217K Buy
11,409
+3,555
+45% +$70.1K ﹤0.01% 4361
2015
Q4 		$210K Sell
7,854
-13,798
-64% -$369K ﹤0.01% 4418
2015
Q3 		$528K Buy
21,652
+14,354
+197% +$478K ﹤0.01% 3908
2015
Q2 		$227K Buy
7,298
+5,996
+461% +$113K ﹤0.01% 4551
2015
Q1 		$18K Buy
1,302
+122
+10% +$1.38K ﹤0.01% 5421
2014
Q4 		$12K Buy
1,180
+8
+0.7% +$65 ﹤0.01% 5553
2014
Q3 		$10K Sell
1,172
-311
-21% -$2.9K ﹤0.01% 5579
2014
Q2 		$18K Buy
1,483
+1,383
+1,383% +$16.5K ﹤0.01% 5416
2014
Q1 		$1K Buy
+100
New +$1.34K ﹤0.01% 5763

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Wells Fargo's HRTX Position: Q1 2026 in Review

Wells Fargo reduced its Heron Therapeutics (HRTX) stake by 63% in Q1 2026, selling an estimated $131K and leaving 66,543 shares worth $53.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5435.

Wells Fargo first reported a position in HRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $14.4M in Q3 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Wells Fargo held 66,543 shares of Heron Therapeutics worth $53.2K as of Q1 2026.
  • Wells Fargo sold 113,077 Heron Therapeutics shares in Q1 2026, an estimated $131K.
  • Heron Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5435 holding.
  • Wells Fargo first reported a position in Heron Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Wells Fargo's Heron Therapeutics position peaked at $14.4M in Q3 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.